# Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

> **NCT01893996** · PHASE4 · COMPLETED · sponsor: **Jonathan Graf** · enrollment: 63 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Cardiovascular Disease

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01893996
- **Lead sponsor:** Jonathan Graf
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893996, "Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01893996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*